Cancer
Do Early-Stage Cancer Surgery Patients Face Risk of Long-Term Opioid Use?
New insights into the complex dynamics of opioid use following curative-intent cancer surgery reveal a concerning trend in long-term opioid...
Promising Outcomes from First-in-Human Trial of DLL3-Targeted Antibody-Drug Conjugate SHR-4849 in Relapsed Small Cell Lung Cancer
First-in-Human Trial Highlights Breakthrough DLL3-Targeted Therapy for Relapsed Small Cell Lung Cancer In a landmark development in the treatment of...
Phase 2 IDeate-Lung01 Trial Shows Ifinatamab Deruxtecan Achieves High Response Rates in Previously Treated Extensive-Stage Small Cell Lung Cancer
In a groundbreaking advancement for small cell lung cancer (SCLC) therapy, recent data unveiled at the International Association for the...
Zidesamtinib Demonstrates Lasting Efficacy in ROS1 TKI-Pretreated NSCLC, Including Cases with CNS Involvement and ROS1 G2032R Mutations
In a groundbreaking advancement for the treatment of ROS1-positive non-small cell lung cancer (NSCLC), a novel investigational agent, zidesamtinib, has...
Crizotinib Does Not Enhance Disease-Free Survival in Resected Early-Stage ALK-Positive NSCLC
In a significant development in the field of thoracic oncology, recent findings from the Phase 3 E4512 clinical trial have...
Ivonescimab Combined with Chemotherapy Enhances Progression-Free Survival in EGFR-Positive NSCLC Patients After Third-Generation EGFR-TKI Treatment
In a groundbreaking advancement for the management of advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR)...
FLAURA2 Trial Demonstrates Enhanced Overall Survival with Osimertinib and Chemotherapy in EGFR-Mutated Advanced NSCLC
In a groundbreaking advancement within the realm of targeted oncology, the international cancer research community has witnessed compelling evidence supporting...
Aumolertinib Combined with Chemotherapy Enhances Progression-Free Survival in NSCLC Patients Harboring EGFR and Tumor Suppressor Gene Alterations: Findings from the ACROSS 2 Phase III Trial
Groundbreaking Phase III Trial Demonstrates Superior Efficacy of Aumolertinib Plus Chemotherapy in Advanced EGFR-Mutant NSCLC In a pivotal advancement for...
Novel Antibody-Drug Conjugate Demonstrates Promising Efficacy in EGFR-Mutated NSCLC Patients
In a groundbreaking development presented at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on...
Phase II Study Finds Iza-Bren Plus Osimertinib Achieves 100% Response Rate in EGFR-Mutated NSCLC
In a groundbreaking advancement for the treatment of non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations,...
-
Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study
-
University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept
-
Bee body mass, pathogens and local climate influence heat tolerance
-
Researchers record first-ever images and data of a shark experiencing a boat strike
-
Groundbreaking Clinical Trial Reveals Lubiprostone Enhances Kidney Function
Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!